Dostarlimab
About
Therapy type: Immunotherapy
Therapy strategy: PD-1/PD-L1 inhibition
Mappings
NCI Thesaurus: Dostarlimab (ncit:C126799)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Dostarlimab | |
| Sensitivity (+) | dMMR | Any solid tumor | Dostarlimab | |
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| Sensitivity (+) | dMMR | Endometrial Carcinoma | Dostarlimab | |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Dostarlimab |